StockData
EyePoint, Inc. logo

EyePoint, Inc. (EYPT) company profile

EYPTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.30−0.01 (-3.80%)

Close on Nov 17, 2026Market cap $25.51MP/E –Yield –

About EyePoint

Laboratory Analytical Instruments, SIC 3826

EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat serious retinal diseases. The company's pipeline utilizes its proprietary bioerodible Durasert E technology designed for sustained intraocular drug delivery. Its primary product candidate is DURAVYU, an investigational sustained-delivery therapy that pairs the tyrosine kinase inhibitor vorolanib with Durasert E to treat vascular endothelial growth factor-mediated retinal conditions, specifically wet age-related macular degeneration and diabetic macular edema. The company also advances EYP-2301 and maintains commercial arrangements regarding YUTIQ and DEXYCU for ophthalmic care.

The company operates manufacturing facilities located in Watertown, Massachusetts, and Northbridge, Massachusetts, and maintains collaboration and commercial supply agreements serving partner markets such as China. EyePoint maintains corporate headquarters in Watertown, Massachusetts.

Summary of the business section of EyePoint's latest annual report, written by StockData.

Company profile

Company

Legal name
EyePoint, Inc.
Headquarters
Watertown, MA
Address
480 Pleasant Street, Suite C400 02472
Phone
(617) 926-5000
Employees
214, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
EYPT
Former tickers
PSDV until May 10, 2018
Exchange
Nasdaq
IPO date
Jan 27, 2005
Shares outstanding
86M, Jul 31, 2026
Public float
$642.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Dec 9, 2020; 1-for-4 reverse, Jun 11, 2008
SEC CIK
1314102
CUSIP
30233G209
ISIN
US30233G2093
FIGI
BBG000F90JX5
Share class FIGI
BBG001SNLCD2
LEI
549300QE1RU34T50MR69
EIN
26-2774444

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jay S. DukerPresident and CEO, Director187,025
George ElstonChief Financial Officer122,470
Ramiro RibeiroChief Medical Officer4,875
Karen L. ZaderejDirector49,100
Nancy LurkerDirector421,235
Reginald J. SandersDirector–
Wendy F. DiciccoDirector9,967
John B. LandisDirector21,400
Stuart DutyDirector–
Goran AndoDirector13,150
Fred HassanDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Jay Duker
$5.57M$13.99M$2.17M$522–
FY2025
Nancy Lurker
$0$0$2.17M$522–
FY2024
Jay Duker
$5.95M-$3.64M$3.35M$213–
FY2024
Nancy Lurker
$0$0$3.35M$213–
FY2023
Jay Duker
$2.92M$12.94M$1.54M$660–
FY2023
Nancy Lurker
$3.74M$23.23M$1.54M$660–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jay Duker
President and Chief Executive Officer
$696.25K$1.61M$2.60M$632.70K$24.59K$5.57M-6%
George Elston
Executive Vice President and Chief Financial Officer
$527.68K$487.34K$781.23K$352.15K$24.98K$2.17M-32%
Ramiro Ribeiro
Chief Medical Officer
$505.01K$487.34K$781.23K$359.77K$23.78K$2.16M-39%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of February 27, 2026, we had 214 employees, all of which were full-time, all located in the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 8, 2025Name changeName changed from EyePoint Pharmaceuticals, Inc. to EyePoint, Inc.
May 18, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 3, 2021Late filingNotification of late filing
Dec 18, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 17, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 11, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 30, 2018Name changeName changed from pSivida Corp. to EyePoint Pharmaceuticals, Inc.
Mar 29, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 12, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 18, 2008Name changeName changed from pSivida LTD to pSivida Corp.
Jan 2, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 9, 2007Late filingNotification of late filing
Dec 30, 2005Late filingNotification of late filing

See a number that looks wrong?